MGC Pharmaceuticals Releases CogniCann Phase II Clinical Trial Results
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of
MGC Pharmaceuticals Ltd (‘MGC Pharma’ or ‘the Company’), a European based bio-pharma company specialising in the production and development of
·        MGC EXECUTES supply and distribution agreement with international pharmaceuticals company Sciensus Rare. · Sciensus Rare is an established international pharmaceutical services
FEBRUARY 2022 marked the one-year anniversary of MGC Pharmaceuticals IPO on the London Stock Exchange, which saw cannabis stocks traded on the platform for the first time in its 320-year history.Â
LAST week began with a number of European cannabis stocks levelling out following dramatic declines days earlier in reaction to
MGC Pharmaceuticals (MXC) has reported its ‘its strongest half-year result to date’ seeing sales more than triple year-on-year, helping lift its stock price out of an all-time low.Â
On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets.Â
MGC Pharmaceutical has reported its strongest ever quarterly sales figures, but a lack of significant progress on its drug trials
THIS has been a transformative year for the European cannabis industry, with growing liberalisation across the continent opening the floodgates
MGC Pharmaceuticals told shareholders attending its Annual General Meeting (AGM) that it is on track to deliver ‘far and away
AFTER launching a patient registry earlier this year further signs the UK’s National Health Service is warming to cannabis medicine
We won’t spam you
© 2024 Prohibition Holdings Ltd. All Rights Reserved.
© 2023 Prohibition Holdings Ltd. All Rights Reserved.